| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(98)03563-6 |
| P698 | PubMed publication ID | 10093981 |
| P2093 | author name string | C Pozzi | |
| F Locatelli | |||
| C Ponticelli | |||
| P Altieri | |||
| G B Fogazzi | |||
| P G Bolasco | |||
| S Andrulli | |||
| P2860 | cites work | Prediction of creatinine clearance from serum creatinine | Q29615603 |
| Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group | Q41134203 | ||
| Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. | Q54259944 | ||
| The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease | Q56867091 | ||
| Doubling of serum creatinine: is it sensitive and relevant? | Q61948413 | ||
| Prognostic Indicators in Childhood IgA Nephropathy | Q67750841 | ||
| Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis | Q68034643 | ||
| IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? | Q68253456 | ||
| Steroid therapy in IgA nephropathy: a retrospective study in heavy proteinuric cases | Q68261439 | ||
| Renal survival rate of IgA nephropathy | Q69893801 | ||
| Controlled Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy | Q70327291 | ||
| Therapeutic perspectives in mesangial IgA nephropathy | Q70670899 | ||
| Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group | Q70989850 | ||
| IgA nephropathy | Q72171768 | ||
| Treatment of IgA nephropathy in children: efficacy of alternate-day oral prednisone | Q72633831 | ||
| Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital | Q72814936 | ||
| P433 | issue | 9156 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | kidney disease | Q1054718 |
| randomized controlled trial | Q1436668 | ||
| P304 | page(s) | 883-887 | |
| P577 | publication date | 1999-03-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Corticosteroids in IgA nephropathy: a randomised controlled trial | |
| P478 | volume | 353 |
| Q94103592 | 15th International Symposium on IgANephropathy - IIgANN 2018, Buenos Aires, September 27-29, 2018: Summaries |
| Q42589021 | A case of crescentic IgA nephropathy treated with prednisolone and cyclophosphamide |
| Q58747430 | A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study |
| Q33932591 | A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy |
| Q24800133 | A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616] |
| Q34557198 | Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy |
| Q38309071 | Abnormal glycosylation of serum IgG in patients with IgA nephropathy. |
| Q34455482 | Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy |
| Q34201444 | An "evidence-based" survey of therapeutic options for IgA nephropathy: assessment and criticism. |
| Q34754190 | Asymptomatic microscopic or dipstick haematuria in adults: which investigations for which patients? A review of the evidence. |
| Q46909287 | Bioavailability effect of methylprednisolone by polymeric micelles |
| Q39809045 | Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy. |
| Q87393387 | Chapter 10: Immunoglobulin A nephropathy |
| Q37050341 | Chronic kidney disease perspectives in Japan and the importance of urinalysis screening |
| Q42995717 | Clinical and histologic response to methylprednisolone pulse therapy in glomerulonephritis |
| Q46744590 | Clinical assessment of low-dose steroid therapy for patients with IgA nephropathy: a prospective study in a single center |
| Q28361134 | Clinical course of patients with IgA nephropathy between combined treatment of immunosuppressive agents and ACE inhibitor and ACE inhibitor alone |
| Q64104936 | Clinical impact of endocapillary proliferation with modified cutoff points in IgA nephropathy patients |
| Q51758616 | Clinical usefulness of the Oxford classification in determining immunosuppressive treatment in IgA nephropathy. |
| Q46788440 | Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study |
| Q46442055 | Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial |
| Q46112109 | Commentary on the KDIGO clinical practice guideline for glomerulonephritis |
| Q45034710 | Comparative study of IgA nephropathy with and without crescents |
| Q37358315 | Comparison of a Bayesian network with a logistic regression model to forecast IgA nephropathy |
| Q41471646 | Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy. |
| Q36767813 | Comparison of effective impact among tonsillectomy alone, tonsillectomy combined with oral steroid and with steroid pulse therapy on long-term outcome of immunoglobulin A nephropathy |
| Q36234400 | Comparison of immunosuppressive therapies for IgA nephropathy after tonsillectomy: three-course versus one-course steroid pulse combined with mizoribine |
| Q50239323 | Comparison of methods of steroid administration combined with tonsillectomy for IgA nephropathy patients |
| Q50230374 | Comparison of oral steroids with tonsillectomy plus steroid pulse therapy in patients with IgA nephropathy |
| Q84196917 | Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy |
| Q90451505 | Complications of Immunosuppression in Glomerular Disease |
| Q53556768 | Con: STOP immunosuppression in IgA nephropathy. |
| Q37108501 | Continental variations in IgA nephropathy among Asians |
| Q59971811 | Continuation of immunosuppressive treatment may be necessary in IgA nephropathy patients with remission of proteinuria: Evaluation by repeat renal biopsy |
| Q44423474 | Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy |
| Q36077744 | Corticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy |
| Q34249313 | Corticosteroid therapy in IgA nephropathy |
| Q36003136 | Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study |
| Q38817381 | Corticosteroids in IgA Nephropathy: Lessons from Recent Studies |
| Q77924803 | Corticosteroids in IgA nephropathy |
| Q41816657 | Corticosteroids in patients with IgA nephropathy and severe chronic renal damage |
| Q58761828 | Corticosteroids pulse therapy and oral corticosteroids therapy for IgA nephropathy patients with advanced chronic kidney disease: results of a multicenter, large-scale, long-term observational cohort study |
| Q44478963 | Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide |
| Q34074851 | Cyclosporin treatment of glomerular diseases |
| Q84230331 | Cyclosporine A vs. methylprednisolone for Henoch-Schönlein nephritis: a randomized trial |
| Q47108714 | Determination of the optimal target level of proteinuria in the management of patients with glomerular diseases by using different definitions of proteinuria |
| Q35025425 | Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset |
| Q73453299 | Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy |
| Q38372995 | Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial |
| Q36843397 | Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study |
| Q47773361 | Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy |
| Q92908883 | Efficacy and safety of immunosuppressive treatment in IgA nephropathy: a meta-analysis of randomized controlled trials |
| Q44045291 | Efficacy of immunosuppressive therapy in IgA nephropathy presenting with isolated hematuria |
| Q81484673 | End-stage renal disease secondary to IgA nephropathy in recessive dystrophic epidermolysis bullosa: a case report |
| Q93069858 | Evaluating a New International Risk-Prediction Tool in IgA Nephropathy |
| Q54579569 | Evaluation of tonsillectomy before kidney transplantation in patients with IgA nephropathy. |
| Q35641499 | Evidence-based guide to slowing the progression of early renal insufficiency |
| Q84978295 | Evidence-based practice guideline for the treatment of CKD |
| Q43083413 | Glomerular disease: ACEIs with or without corticosteroids in IgA nephropathy? |
| Q81776040 | Glomerulonephritis |
| Q88673238 | Glucocorticoids in the treatment of patients with primary focal segmental glomerulosclerosis and moderate proteinuria |
| Q90461387 | Has The Time Arrived to Refine The Indications of Immunosuppressive Therapy and Prognosis in IgA Nephropathy? |
| Q80249730 | High-dose intravenous immunoglobulin pulse therapy in patients with progressive immunoglobulin A nephropathy: a long-term follow-up |
| Q51834649 | IgA Nephropathy. |
| Q36577108 | IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors |
| Q33715857 | IgA nephropathy with minimal change disease. |
| Q24188035 | Immunosuppressive agents for treating IgA nephropathy |
| Q24247680 | Immunosuppressive agents for treating IgA nephropathy |
| Q90254423 | Immunosuppressive agents for treating IgA nephropathy |
| Q35885198 | Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. |
| Q36585452 | Improved renal survival in Japanese children with IgA nephropathy |
| Q39178756 | Inflammation in IgA nephropathy. |
| Q36887229 | International Study of Health Care Organization and Financing for renal replacement therapy in Italy: an evolving reality |
| Q38094055 | Is a legacy effect possible in IgA nephropathy? |
| Q39229309 | Is there a role for immunosuppression in immunoglobulin A nephropathy? |
| Q41847071 | Leukocytoclastic Vasculitis Associated with a New Anticoagulant: Rivaroxaban |
| Q28194582 | Liver and kidney diseases |
| Q36159078 | Long-term efficacy of tonsillectomy as a treatment in patients with IgA nephropathy: a meta-analysis |
| Q46715751 | Long-term follow-up of patients with IgA nephropathy treated with prednisolone and cyclophosphamide therapy |
| Q35743170 | Long-term kidney survival analyses in IgA nephropathy patients under steroids therapy: a case control study. |
| Q35030576 | Long-term results of a randomized controlled trial in childhood IgA nephropathy |
| Q36297037 | Management of leukocytoclastic vasculitis. |
| Q34747330 | Military nephrology: magnitude of rates of deterioration in renal function |
| Q51734842 | Moderator's view: Treatment of IgA nephropathy-getting comfortable with uncertainty. |
| Q35657080 | Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children |
| Q50740436 | Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment. |
| Q37467985 | Nationwide survey on current treatments for IgA nephropathy in Japan |
| Q26786248 | New developments in the genetics, pathogenesis, and therapy of IgA nephropathy |
| Q64230728 | New strategies and perspectives on managing IgA nephropathy |
| Q51595672 | New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. |
| Q36761841 | Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin A nephropathy |
| Q37524989 | Periodontal disease bacteria specific to tonsil in IgA nephropathy patients predicts the remission by the treatment. |
| Q34109103 | Perspective on future therapy of vasculitis |
| Q44099013 | Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions |
| Q34381920 | Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids |
| Q73945062 | Prevalence and predictors of recurrent IgA nephropathy following renal transplantation |
| Q52309425 | Primary IgA nephropathy: current challenges and future prospects. |
| Q35128270 | Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan |
| Q38575862 | Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression. |
| Q39372948 | Proposal of remission criteria for IgA nephropathy |
| Q40527567 | Pulmonary abscess due to leflunomide use in rheumatoid arthritis: a case report |
| Q24791691 | Race/ethnicity and disease severity in IgA nephropathy |
| Q34658876 | Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. |
| Q33863555 | Rationales for treating IgA nephropathies |
| Q33811023 | Recent advances: nephrology |
| Q53188667 | Reduction of proteinuria by therapeutic intervention improves the renal outcome of elderly patients with IgA nephropathy. |
| Q57945954 | References |
| Q36199539 | Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy. |
| Q37251705 | Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price? |
| Q38641845 | Renal Involvement in Idiopathic Inflammatory Myopathies |
| Q36895544 | Renal transplantation in high-risk patients |
| Q34747324 | Review of cases of IgA nephropathy |
| Q43703528 | Role of proteinuria reduction in the progression of IgA nephropathy |
| Q90295317 | Schisandrin B Improves the Renal Function of IgA Nephropathy Rats Through Inhibition of the NF-κB Signalling Pathway |
| Q47171676 | Seasonal proteinuria changes in IgA nephropathy patients after proteinuria remission |
| Q86392703 | Sequential therapy with cyclophosphamide and mycophenolic acid in patients with progressive immunoglobulin A nephropathy: a long-term follow-up |
| Q47107237 | Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy |
| Q73834703 | Steroid and cyclophosphamide in IgA nephropathy |
| Q79273215 | Steroids and immunoglobulin A nephritis |
| Q33886910 | Steroids in the treatment of IgA nephropathy to the improvement of renal survival: a systematic review and meta-analysis |
| Q36461600 | The IgA nephropathy treatment dilemma |
| Q53745800 | The Japanese Histologic Classification and T-score in the Oxford Classification system could predict renal outcome in Japanese IgA nephropathy patients. |
| Q38409163 | The Role of TNF Superfamily Member 13 in the Progression of IgA Nephropathy |
| Q27005109 | The Treatment of IgA Nephropathy |
| Q39139491 | The clinical course of IgA nephropathy after kidney transplantation and its management |
| Q37090470 | The improvement of renal survival with steroid pulse therapy in IgA nephropathy |
| Q42215030 | The negative effect of initial high-dose methylprednisolone and tapering regimen for acute respiratory distress syndrome: a retrospective propensity matched cohort study |
| Q37115267 | The predictive value of attenuated proteinuria at 1 year after steroid therapy for renal survival in patients with IgA nephropathy |
| Q35852475 | Therapeutic approach of patients with IgA nephropathy |
| Q100764493 | Tonsillectomy Monotherapy for IgA Nephropathy: A Case Series |
| Q36963938 | Tonsillectomy reduces recurrence of IgA nephropathy in mesangial hypercellularity type categorized by the Oxford classification. |
| Q86715208 | Treatment of IgA nephropathy |
| Q38094888 | Treatment of IgA nephropathy and Henoch-Schönlein nephritis |
| Q38689787 | Treatment of IgA nephropathy with renal insufficiency |
| Q37939849 | Treatment of IgA nephropathy: an update |
| Q46309050 | Treatment of severe Henoch-Schönlein and immunoglobulin A nephritis. A single center experience |
| Q53093584 | Treatment protocol with pulse and oral steroids for IgA Nephropathy after kidney transplantation. |
| Q45966383 | Twice daily fractionated dose administration of prednisolone compared to standard once daily administration to patients with glomerulonephritis or with kidney transplants. |
| Q36447934 | Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects |
| Q51250753 | Validation of the Japanese histologic classification 2013 of immunoglobulin A nephropathy for prediction of long-term prognosis in a Japanese single-center cohort. |
| Q34284540 | Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments |
| Q38860793 | Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy? |
| Q52546301 | [Berger's disease in childhood] |
| Q79181948 | [IgA nephropathy: frequent, but rarely diagnosed] |
| Q52767203 | [Leukocytoclastic vasculitis]. |
| Q81153388 | [Recessive dystrophic epidermolysis bullosa (Hallopeau-Siemens) with IgA nephropathy: 4 cases] |
| Q79181938 | [Treatment of glomerulonephritis] |
Search more.